Deanna L. Russell

Deanna L. Russell

Auto-generated profile, based on publicly available information

Deanna L. Russell

Translational Medicine, Oncology R&D, AstraZeneca, Boston, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
HWHong Wang
Hong Wang
LHLiping Hu
Liping Hu
KDKnut Dalen
Knut Dalen
HDHeidi Dorward
Heidi Dorward
AMAmy Marcinkiewicz
Amy Marcinkiewicz
CSCarole Sztalryd
Carole Sztalryd
Lipolysis is an important metabolic pathway controlling energy homeostasis through degradation of triglycerides stored in lipid droplets and release of fatty acids. Lipid droplets of mammalian cells are coated with one or more members of the PAT protein family, which serve important functions in regulating lipolysis. In this study, we investigate the mechanisms by which PAT family members, perilipin A, adipose differentiation-related protein (ADFP), and LSDP5, control lipolysis catalyzed by hormone-sensitive lipase (HSL), a major lipase in adipocytes and several non-adipose cells. We applied fluorescence microscopic tools to analyze proteins in situ in cultured Chinese hamster ovary cells using fluorescence recovery after photobleaching and anisotropy Forster resonance energy transfer. Fluorescence recovery after photobleaching data show that ADFP and LSDP5 exchange between lipid droplet and cytoplasmic pools, whereas perilipin A does not. Differences in protein mobility do not correlate with PAT protein-mediated control of lipolysis catalyzed by HSL or endogenous lipases. Forster resonance energy transfer and co-immunoprecipitation experiments reveal that each of the three PAT proteins bind HSL through interaction of the lipase with amino acids within the highly conserved amino-terminal PAT-1 domain. ADFP and LSDP5 bind HSL under basal conditions, whereas phosphorylation of serine residues within three amino-terminal protein kinase A consensus sequences of perilipin A is required for HSL binding and maximal lipolysis. Finally, protein kinase A-mediated phosphorylation of HSL increases lipolysis in cells expressing ADFP or LSDP5; in contrast, phosphorylation of perilipin A exerts the major control over HSL-mediated lipolysis when perilipin is the main lipid droplet protein.

1 December 2003 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
VAVictor Abkevich
Victor Abkevich
NCNicola J. Camp
Nicola J. Camp
CHCharles H. Hensel
Charles H. Hensel
CNChris D. Neff
Chris D. Neff
DRDeanna L. Russell
Deanna L. Russell
LCLisa A. Cannon-Albright
Lisa A. Cannon-Albright

13 February 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
BBBenjamin Besse
Benjamin Besse
EPElvire Pons-Tostivint
Elvire Pons-Tostivint
KPKeunchil Park
Keunchil Park
SHSylvia Hartl
Sylvia Hartl
PFPatrick M. Forde
Patrick M. Forde
JHJohn V. Heymach
John V. Heymach
For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common. Understanding mechanisms of resistance—which can include defects in DNA damage response and repair pathways, alterations or functional mutations in STK11/LKB1, alterations in antigen-presentation pathways, and immunosuppressive cellular subsets within the tumor microenvironment—and developing effective therapies to overcome them, remains an unmet need. Here the phase 2 umbrella HUDSON study evaluated rational combination regimens for advanced NSCLC following failure of anti-PD-(L)1-containing immunotherapy and platinum-doublet therapy. A total of 268 patients received durvalumab (anti-PD-L1 monoclonal antibody)–ceralasertib (ATR kinase inhibitor), durvalumab–olaparib (PARP inhibitor), durvalumab–danvatirsen (STAT3 antisense oligonucleotide) or durvalumab–oleclumab (anti-CD73 monoclonal antibody). Greatest clinical benefit was observed with durvalumab–ceralasertib; objective response rate (primary outcome) was 13.9% (11/79) versus 2.6% (5/189) with other regimens, pooled, median progression-free survival (secondary outcome) was 5.8 (80% confidence interval 4.6–7.4) versus 2.7 (1.8–2.8) months, and median overall survival (secondary outcome) was 17.4 (14.1–20.3) versus 9.4 (7.5–10.6) months. Benefit with durvalumab–ceralasertib was consistent across known immunotherapy-refractory subgroups. In ATM-altered patients hypothesized to harbor vulnerability to ATR inhibition, objective response rate was 26.1% (6/23) and median progression-free survival/median overall survival were 8.4/22.8 months. Durvalumab–ceralasertib safety/tolerability profile was manageable. Biomarker analyses suggested that anti-PD-L1/ATR inhibition induced immune changes that reinvigorated antitumor immunity. Durvalumab–ceralasertib is under further investigation in immunotherapy-refractory NSCLC.ClinicalTrials.gov identifier: NCT03334617

7 August 2006 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SSSteven Stone
Steven Stone
VAVictor Abkevich
Victor Abkevich
DRDeanna L. Russell
Deanna L. Russell
RRRobyn Riley
Robyn Riley
KTKirsten Timms
Kirsten Timms
DSDonna Shattuck
Donna Shattuck
The molecular etiology of obesity predisposition is largely unknown. Here, we present evidence that genetic variation in TBC1D1 confers risk for severe obesity in females. We identified a coding variant (R125W) in TBC1D1 that segregated with the disease in 4p15–14-linked obesity pedigrees. In cases derived from pedigrees with the strongest linkage evidence, the variant was significantly associated with obesity (P=0.000007) and chromosomes carrying R125W accounted for the majority of the evidence that originally linked 4p15–14 with the disease. In addition, by selecting families that segregated R125W with obesity, we were able to generate highly significant linkage evidence for an obesity predisposition locus at 4q34–35. This result provides additional and confirming evidence that R125W affects obesity susceptibility, delimits the location of an obesity gene at 4q34–35 and identifies a gene/gene interaction that influences the risk for obesity predisposition. Finally, although the function of TBC1D1 is unknown, the protein is structurally similar to a known regulator of insulin-mediated Glut4 translocation.

1 June 2002 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SSSteven Stone
Steven Stone
VAVictor Abkevich
Victor Abkevich
SHSteven C. Hunt
Steven C. Hunt
AGAlexander Gutin
Alexander Gutin
DRDeanna L. Russell
Deanna L. Russell
DSDonna Shattuck
Donna Shattuck

1 May 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BSBen Sidders
Ben Sidders
PZPei Zhang
Pei Zhang
KGKelly Goodwin
Kelly Goodwin
GOGreg O'Connor
Greg O'Connor
DRDeanna L. Russell
Deanna L. Russell
KSKris Sachsenmeier
Kris Sachsenmeier
Purpose: There are several agents in early clinical trials targeting components of the adenosine pathway including A2AR and CD73. The identification of cancers with a significant adenosine drive is critical to understand the potential for these molecules. However, it is challenging to measure tumour adenosine levels at scale, thus novel, clinically tractable biomarkers are needed. Experimental Design: We generate a gene expression signature for the adenosine signaling using regulatory networks derived from the literature and validate this in patients. We apply the signature to large cohorts of disease from TCGA and cohorts of immune checkpoint inhibitor treated patients. Results: The signature captures baseline adenosine levels in vivo (r2=0.92, p=0.018), is reduced after small molecule inhibition of A2AR in mice (r2 = -0.62, p=0.001) & humans (reduction in 5 of 7 patients (70%)) and is abrogated after A2AR knock-out. Analysis of TCGA confirms a negative association between adenosine and overall survival (OS, HR=0.6, p<2.2e-16) as well as progression free survival (PFS, HR=0.77, p=0.0000006). Further, adenosine signaling is associated with reduced OS (HR=0.47, p<2.2e-16) and PFS (HR=0.65, p=0.0000002) in CD8+ T-cell infiltrated tumours. Mutation of TGFβ superfamily members are associated with enhanced adenosine signaling and worse OS (HR=0.43, p<2.2e-16). Finally, adenosine signaling is associated with reduced efficacy of anti-PD1 therapy in published cohorts (HR=0.29, p=0.00012). Conclusions: These data support the adenosine pathway as a mediator of a successful anti-tumour immune response, demonstrate the prognostic potential of the signature for immuno-therapy and inform patient selection strategies for adenosine pathway modulators currently in development.